Introduction: Innate lymphoid cells (ILCs), have emerged as novel important immune effector cells, playing a critical role also in tumor immune-surveillance. Recently, it was shown that the number of ILCs in patients with different types of cancer is significantly reduced after chemotherapy/radiotherapy as compared to healthy donors. However, so far, no data on ILC frequency, subset distribution and function in patients with melanoma are available. Therefore, we analyzed the frequency, subset distribution and function of ILCs in a murine model of melanoma with/without treatment, a parameter that is of paramount importance to understand the role of ILCs during melanoma and to assess the impact of current treatments on this type of cancer. Methods: C57/BL6 mice were injected with B16F10 murine melanoma cell line (1 x 106 cells/mouse, subcutaneous). Tumor growth monitored. Once tumors reached 12mm in size, the mice were sacrificed and tumor cells subjected to flow-cytometry and cell culture to identify the ILC subclasses in the tumor. Results: Our findings establish, for the first time in melanoma at diagnosis, base-line reference values for ILC frequency and function, as well as the ILC subtype distribution. Conclusion: Our studies extend previously published work on changes in innate lymphoid cells. Our findings will help better understanding of tumor microenvironment and its interaction with immune system. These values indicate the potential of ILCs as crucial players in the treatment of cancer, specifically melanoma. Citation Format: Blake Christianson, James Walker, Marsha Kocherla, Xu Qin, Jack C. Yu, Babak Baban. Innate lymphoid cells (ILCs) in murine melanoma: A new paradigm in cancer immunity. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr A01.
Introduction: Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. Del-1 has an endothelial cell–restricted pattern, particularly in the embryo. However, our data now for the first time provide evidence that melanoma cells express Del-1. The relatively newly described cancer stem cells (CSCs) are tumor-initiating cells (TICs) that often survive therapy and give rise to second-line tumors by self-renewal and differentiation into multiple cell types. CSCs are proposed to persist in tumors as a distinct population and to cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially those with metastatic disease. Methods: C57/BL6 mice were injected with B16F10 murine melanoma cell line (1 x 106 cells/mouse, subcutaneous). Tumor growth monitored. Controls (Group 2) received vehicle only (PBS). Once the first tumor reached 12mm in size, the mice were sacrificed and tumor cells subjected to flow-cytometry, and statistical analysis, and p-values <0.05 considered significant. our novel findings suggest a regulatory role for Del-1 in cancer. Alteration of inflammatory indices, apoptosis, and necroptosis with ultimate affects on tumor size and growth were all may be potentially regulated partially by a Del-1 dependent mechanism. Results: Our data showed for the first time that DEL-1 was expressed by CSCs as well as typic non stem cells tumor cells in a murine melanoma model. These DEL-1-expressing CSCs may be palying a role in tumor angiogenesis. Further, DEL-1 is capable of suppressing T lymphocyte infiltration into the tumor microenvironment. our novel findings suggest a regulatory role for Del-1 in cancer. Alteration of inflammatory indices, apoptosis, and necroptosis with ultimate affects on tumor size and growth (by affecting Cancer Stem Cells) were all may be potentially regulated partially by a Del-1 dependent mechanism. Conclusion: Our data propose a novel hypothesis that development of tumor and CSCs activity may be affected by angiogenic and regulatory nature of Del-1. Furthermore, our results suggest a therapeutic role for Del-1 as a novel modality in cancer treatment. Citation Format: James Walker, marsha kocherla, Blake christianson, Xu qin, Jack C. yu, Babak baban. The crosstalk between developmental endothelial locus 1 (DEL-1) and cancer stem cells in murine melanoma: A potential modality of local control. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr A23.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.